Neutralization of TGF-beta by anti-TGF-beta antibody attenuates kidney hypertrophy and the enhanced extracellular matrix gene expression in STZ-induced diabetic mice - PubMed (original) (raw)

Comparative Study

Neutralization of TGF-beta by anti-TGF-beta antibody attenuates kidney hypertrophy and the enhanced extracellular matrix gene expression in STZ-induced diabetic mice

K Sharma et al. Diabetes. 1996 Apr.

Abstract

Diabetic nephropathy is characterized by renal hypertrophy, thickening of basement membranes, and accumulation of extracellular matrix in the glomerular mesangium and the interstitium. Our previous investigations have shown that high glucose concentration increases transforming growth factor (TGF)-beta1 mRNA in mesangial and proximal tubule cells and that treatment with anti-TGF-beta antibody results in prevention of the effects of high glucose on cell growth (e.g., induction of cellular hypertrophy) and the stimulation of collagen biosynthesis. We evaluated in vivo the functional role of the renal TGF-beta system in diabetic kidney disease by treatment of streptozotocin-induced diabetic mice with either a neutralizing monoclonal antibody against TGF-beta1, -beta2, and -beta3 (alphaT) or nonimmune murine IgG for 9 days. Diabetic mice given IgG demonstrated total kidney and glomerular hypertrophy, significantly elevated urinary TGF-beta1 protein, and increased mRNAs encoding TGF-beta1, type II TGF-beta receptor, alpha1(IV) collagen, and fibronectin. Treatment of diabetic mice with alphaT prevented glomerular hypertrophy, reduced the increment in kidney weight by approximately 50%, and significantly attenuated the increase in mRNA levels without having any effect on blood glucose. The antibody was without significant effect on mRNA levels in nondiabetic mice. This is the first demonstration that the early characteristic features of diabetic renal involvement, which include hypertrophy and increased matrix mRNAs, are largely mediated by increased endogenous TGF-beta activity in the kidney and that they can be significantly attenuated by treatment with neutralizing anti-TGF-beta antibodies.

PubMed Disclaimer

Similar articles

• Expression of transforming growth factor-beta and type IV collagen in early streptozotocin-induced diabetes.
  Park IS, Kiyomoto H, Abboud SL, Abboud HE. Park IS, et al. Diabetes. 1997 Mar;46(3):473-80. doi: 10.2337/diab.46.3.473. Diabetes. 1997. PMID: 9032105
• Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-beta antibody in db/db diabetic mice.
  Ziyadeh FN, Hoffman BB, Han DC, Iglesias-De La Cruz MC, Hong SW, Isono M, Chen S, McGowan TA, Sharma K. Ziyadeh FN, et al. Proc Natl Acad Sci U S A. 2000 Jul 5;97(14):8015-20. doi: 10.1073/pnas.120055097. Proc Natl Acad Sci U S A. 2000. PMID: 10859350 Free PMC article.
• Therapy with antisense TGF-beta1 oligodeoxynucleotides reduces kidney weight and matrix mRNAs in diabetic mice.
  Han DC, Hoffman BB, Hong SW, Guo J, Ziyadeh FN. Han DC, et al. Am J Physiol Renal Physiol. 2000 Apr;278(4):F628-34. doi: 10.1152/ajprenal.2000.278.4.F628. Am J Physiol Renal Physiol. 2000. PMID: 10751224
• The key role of the transforming growth factor-beta system in the pathogenesis of diabetic nephropathy.
  Chen S, Hong SW, Iglesias-de la Cruz MC, Isono M, Casaretto A, Ziyadeh FN. Chen S, et al. Ren Fail. 2001 May-Jul;23(3-4):471-81. doi: 10.1081/jdi-100104730. Ren Fail. 2001. PMID: 11499562 Review.
• Hyperglycemia and diabetic kidney disease. The case for transforming growth factor-beta as a key mediator.
  Sharma K, Ziyadeh FN. Sharma K, et al. Diabetes. 1995 Oct;44(10):1139-46. doi: 10.2337/diab.44.10.1139. Diabetes. 1995. PMID: 7556948 Review.

Cited by

• Romosozumab rescues impaired bone mass and strength in a murine model of diabetic kidney disease.
  Kohler R, Segvich DM, Reul O, Metzger CE, Allen MR, Wallace JM. Kohler R, et al. Bone Rep. 2024 May 12;21:101774. doi: 10.1016/j.bonr.2024.101774. eCollection 2024 Jun. Bone Rep. 2024. PMID: 38778834 Free PMC article.
• Treatment for type 2 diabetes and diabetic nephropathy by targeting Smad3 signaling.
  He H, Wang H, Chen X, Zhong Y, Huang XR, Ma RC, Wang C, Lan HY. He H, et al. Int J Biol Sci. 2024 Jan 1;20(1):200-217. doi: 10.7150/ijbs.87820. eCollection 2024. Int J Biol Sci. 2024. PMID: 38164169 Free PMC article.
• [The Role of TGF-β1/SMAD in Diabetic Nephropathy: Mechanisms and Research Development].
  Wang Y, Guo J, Shao B, Chen H, Lan H. Wang Y, et al. Sichuan Da Xue Xue Bao Yi Xue Ban. 2023 Nov 20;54(6):1065-1073. doi: 10.12182/20231160108. Sichuan Da Xue Xue Bao Yi Xue Ban. 2023. PMID: 38162063 Free PMC article. Chinese.
• Bone morphogenetic protein-7 attenuates pancreatic damage under diabetic conditions and prevents progression to diabetic nephropathy via inhibition of ferroptosis.
  Song SH, Han D, Park K, Um JE, Kim S, Ku M, Yang J, Yoo TH, Yook JI, Kim NH, Kim HS. Song SH, et al. Front Endocrinol (Lausanne). 2023 May 24;14:1172199. doi: 10.3389/fendo.2023.1172199. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 37293506 Free PMC article.
• Empagliflozin increases kidney weight due to increased cell size in the proximal tubule S3 segment and the collecting duct.
  Sinha F, Federlein A, Biesold A, Schwarzfischer M, Krieger K, Schweda F, Tauber P. Sinha F, et al. Front Pharmacol. 2023 Mar 23;14:1118358. doi: 10.3389/fphar.2023.1118358. eCollection 2023. Front Pharmacol. 2023. PMID: 37033639 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Ovid Technologies, Inc.
  • Silverchair Information Systems

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information